Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: Report of a case and review of the literature with demonstration of genes alteration into the same tumor cells-Reference-Cited by-同舟云学术

Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: Report of a case and review of the literature with demonstration of genes alteration into the same tumor cells

Published:2014-11 Issue:2 Volume:86 Page:291-295
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Baldi Licia,Mengoli Maria Cecilia,Bisagni Alessandra^ORCID,Banzi Maria Chiara,Boni Corrado,Rossi Giulio

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference21 articles.

1. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer;Gainor;Clin Cancer Res,2013

2. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK;Shaw;J Clin Oncol,2009

3. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors;Sasaki;Cancer Res,2011

4. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation;Kuo;J Thorac Oncol,2010

5. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations;Tiseo;Lung Cancer,2011

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-Induced Liver Injury Associated with Alk Inhibitors: A Pharmacovigilance Analysis of the Fda Adverse Event Reporting System (Faers);2024

2. Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC;International Journal of Molecular Sciences;2023-02-18

3. Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway;npj Precision Oncology;2023-01-23

4. Genomic landscape of lung adenocarcinomas in different races;Frontiers in Oncology;2022-09-28

5. Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study;Frontiers in Pharmacology;2022-03-17